ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PLUR
JSPR (36) SCLX (40) DYAI (31) ABOS (33) ⌘ Pro Terminal →

Pluri Inc. (PLUR) — RQD Stock Rating Cockpit

$1.24 +3.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.25

Pluri Inc. (PLUR) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $16.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PLUR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PLUR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Pluri Inc. (NASDAQ: PLUR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.24 (+3.33% 1D, market cap $16.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PLUR ranks #647 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PLUR compare to JSPR and SCLX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PLUR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 49.0%, and ROIC of -35.0%. By comparison, JSPR (Jasper Therapeutics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $17.3M) and SCLX (Scilex Holding Company) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $15.7M). Among the 5-stock peer group, PLUR leads on earnings multiple (N/A) while PLUR leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PLUR?
▼

Per PLUR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001158780), Pluri Inc. generated $1.3M in revenue (+309.8% YoY), -$22.6M in net income, and -$19.8M in free cash flow against $30.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.25 (+0.41%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (8)Whales (9)SEC (8)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-10.5% Base Target
$5 Bull$1 Base$1 Bear
📬 FREE PLUR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PLUR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY PLUR SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 49% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
26
Grade E$0.94-4.3% Next Q
Q2 (-2Q)
29
Grade E$0.90+32.2% Next Q
Q3 (-1Q)
31
Grade E$1.19+4.2% Next Q
Current
34
Grade E$1.24-8.7% Hist 90D α
Trajectory: E (26) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PLUR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PLUR currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.15) and Max Pain ($1.30) forces dealer call-delta covering toward $5.11.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PLUR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PLUR Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
60.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE10% OF RANGE
L: $1$1.24H: $5
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 14 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on PLUR

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 49.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (30)

12/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like PLUR
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PLUR)

  • ✓Walkthrough of PLUR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PLUR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -63.31%⚡ TESTING RESISTANCE
2026-11-03O $1.20H $1.24L $1.20C $1.24VOL 29.3K
RES: $1.40SUP: $0.63SMA50: $1.15SMA200: $2.37
$4.10$3.22$2.34$1.46$0.58RES $1.40SUP $0.63$1.242026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PLUR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PLUR Butterfly Map → + Track PLUR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +309.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PLUR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PLUR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PLUR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PLUR)

Health Care Rank #647 of 1015 ⚔️ JSPR vs PLUR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PLUR vs. JSPR, SCLX, DYAI, ABOS)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Pluri Inc. (PLUR) ranks #647 by composite RQD confidence (34/100, grade E) and #841 by equity capitalization ($16.7M). Within this direct 5-issuer industry benchmark cohort, PLUR leads on earnings valuation at N/A trailing P/E, while PLUR leads on capital efficiency and profitability with -35.0% ROIC and 49.0% gross margin. SCLX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with PLUR at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PLUR ACTIVE
Pluri Inc.
E 34/100 — 49.0% -35.0% +3.33% $16.7M Benchmark Subject
JSPR
Jasper Therapeutics Inc.
D- 36/100 — — -35.0% -2.22% $17.3M /jspr-vs-plur →
SCLX
Scilex Holding Company
D- 40/100 — 96.0% -35.0% -10.19% $15.7M /sclx-vs-plur →
DYAI
Dyadic International Inc.
E 31/100 — 24.9% -35.0% +5.32% $15.2M /dyai-vs-plur →
ABOS
Acumen Pharmaceuticals Inc.
E 33/100 — — -35.0% -90.82% $15.2M /abos-vs-plur →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001158780 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Pluri Inc. (PLUR) reported GAAP revenue of $1.3M (+309.8% vs. FY2024 revenue of $326.0K , and +365.5% cumulative change since FY2023) , GAAP net income of -$22.6M, operating cash flow of -$18.2M, and free cash flow of -$19.8M (-8.1% YoY). On the balance sheet, PLUR closed FY2025 with $30.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $1.3M -$22.6M -$18.2M -$19.8M $30.6M —
FY2024 (FY) 2024-06-30 $326.0K $21.3M -$18.0M -$18.3M $30.9M —
FY2023 (FY) 2023-06-30 $287.0K $28.9M -$22.9M -$22.9M — —

3. PLUR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PLUR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Pluri Inc. (NASDAQ: PLUR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.24 (+3.33% 1D, market cap $16.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PLUR ranks #647 in composite RQD confidence.

How does PLUR compare to JSPR and SCLX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PLUR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 49.0%, and ROIC of -35.0%. By comparison, JSPR (Jasper Therapeutics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $17.3M) and SCLX (Scilex Holding Company) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $15.7M). Among the 5-stock peer group, PLUR leads on earnings multiple (N/A) while PLUR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PLUR?

Per PLUR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001158780), Pluri Inc. generated $1.3M in revenue (+309.8% YoY), -$22.6M in net income, and -$19.8M in free cash flow against $30.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PLUR trading relative to its 50-day, 200-day, and 52-week technical levels?

PLUR last traded at $1.24 (+3.33% on volume of 29,340 shares), positioning the stock +7.83% above its 50-day simple moving average ($1.15) and -47.68% below its 200-day simple moving average ($2.37). Across its 52-week range of $0.85 to $4.87, PLUR sits at the 9.7% percentile with a 14-day RSI of 60.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.09 to $1.39).

Direct Sub-Reports: PLUR RQD Cockpit PLUR 12M Forecast PLUR Earnings & Move PLUR Dividends & DRIP PLUR Insiders & 13F PLUR Whale Options PLUR Profit Sankey PLUR News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

PLUR — Pluri Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Pluri Inc. (PLUR) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.24 (+3.33% 1D, market capitalization $16.7M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 49.0%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Pluri Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The company's market capitalization is $0.0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Pluri Inc. (PLUR) reported $1.3M in annual revenue (up from $326.0K in FY2024, +309.8% YoY) and -$22.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($287.0K revenue, $28.9M net income) through FY2025, PLUR scaled operating cash flow to -$18.2M and free cash flow to -$19.8M, backed by $30.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $0.85 – $4.87 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not identify upstream suppliers, downstream customers, or sector correlation partners. The only linkage evident in the news wire is the ZEO relationship referenced in the headlines, which bears on the company's U.S. Commercialization path and on the chairman-linked loan arrangement. A prospective investor should watch whether the ZEO transactions alter the company's revenue base and whether the loan obligation constrains liquidity given cash of $4.7M against FY 2025 negative free cash flow of -$19.8M.

  • Key Question #1: Can PLUR sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.3M and free cash flow of -$19.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PLUR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PLUR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pluri Inc. (PLUR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PLUR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PLUR Bull vs. Bear Conversation Board — What's Your Call at $1.24?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PLUR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PLUR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $1.61 (+29.8%)
📌 Pinned Debate

Institutional accumulation and ZEO-linked commercialization headlines could catalyze a reversal from a $1.2 share price that sits near

Here is why I am bullish on PLUR here at $1.24: Institutional accumulation and ZEO-linked commercialization headlines could catalyze a reversal from a $1.2 share price that sits near the low end of its $0.85–$4.87 52-week range.. Compare PLUR's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $1.18 are getting bought.

SectorRotator 🐂 BULL

@RedlineAuditor Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (49.0%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $1.00 (-19.4%)
Spot @ $1.24

Valuation & margin reality check on PLUR at $1.24 before chasing here

Sitting on the sidelines or leaning short PLUR above $1.24. Valuation & margin reality check on PLUR at $1.24 before chasing here. Until Fundamental Cash Engine (8/20) and FCF yield (0.0%) inflect higher, upside is capped near $4.87.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%